Kyron

kyron.bio is a French biotechnology company based at the Paris Biotech Santé incubator in Cochin Hospital, Paris, that develops a platform for precision control of N-glycosylation in therapeutic proteins and antibodies. Glycosylation is the cellular process by which sugar molecules (glycans) are attached to the surface of biologics; in standard biomanufacturing this process is inconsistent and produces a mixture of glycan structures that can trigger immune responses against the drug or reduce its efficacy. The company positions unwanted immune recognition of antibody therapeutics as a growing burden for biopharma, particularly for chronic-disease patients treated over long periods and for novel modalities that fail at the Phase I safety stage.

The platform combines two components: genetically engineered Chinese Hamster Ovary (CHO) production cell lines that allow control over the glycosylation process, and a proprietary glycan-engineering toolbox applied to the antibody itself to prevent unwanted immune attack, improve performance and generate new intellectual property. The company describes the platform as a scalable, plug-and-play solution compatible with standard biopharma manufacturing, reportedly achieving over 97% consistency in glycan structures, and applies it across oncology, autoimmune disease and infectious disease. A directory listing describes the company more broadly as using synthetic biology to build cell lines that increase protein yield, activity and stability, citing up to 10x improvements and a completed proof-of-concept showing a 3x yield improvement for hormone production.

The team listed on the company website comprises founder and CEO Dr. Emilia McLaughlin plus roles in R&D, lab operations, science and administration (Head of R&D, Head of Lab & Ops, Senior Scientist, Lab Engineer, Research Associate, Founder Associate, Executive Assistant). A separate directory entry lists Emilia McLaughlin as President & CSO and gives an administrative address at 10 rue de Penthièvre, 75008 Paris.

Founding story

kyron.bio was founded in 2022 out of the Entrepreneur First Paris cohort, following Dr. Emilia McLaughlin's PhD in cellular and molecular biology. Her doctoral work at Institut Pasteur Paris studying rare single-cell organisms informed the company's approach to drug development, which centres on using glycans as a design tool. The company states it developed the first scalable, patent-protected method to control glycosylation for this purpose.

Business model

The company operates as a platform biotech, offering its glycan-engineering technology as a scalable, plug-and-play solution compatible with standard biopharma manufacturing processes and seeking partnerships with pharmaceutical companies developing complex therapeutics. It also pursues its own preclinical development, with seed proceeds allocated to platform development, team expansion and preclinical studies.

Traction

Reported milestones include a first patent filed in June 2022, a completed proof-of-concept showing 3x yield improvement for hormone production, a second proof-of-concept study with the University of Denmark, a €5.5 million seed round in May 2025, an EIC Transition project backed by the European Innovation Council, relocation to expanded lab space at Paris Biotech Santé (2025), and a strategic partnership with Servier announced in 2026. The website lists eight team members.

Latest developments

The company website announces a strategic partnership with Servier under 2026, following its 2025 relocation to Hôpital Cochin as part of the Paris Biotech Santé incubator and the May 2025 €5.5 million seed round, which coincided with the launch of its EIC Transition project.